CD274 and cancer: It is tempting to suggest that revising the “Cancer immunoediting” concept to take into consideration the migratory behavior of anti-tumoral T cells might contribute to achieve a more comprehensive view of anti-PD-1/PD-L1 mechanism of action, and consequently to improve anti-cancer therapy, for example by combining ICB with drugs able to modulate T-cell homing pathways.